Kura Oncology (KURA) Net Equity Issued and Repurchased (2015 - 2020)

Kura Oncology (KURA) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $324.1 million in Q4 2020.

• On a quarterly basis, Net Equity Issued and Repurchased rose 1543433.33% year-over-year to $324.1 million in Q4 2020; TTM through Dec 2020 was $432.0 million, a 136.58% increase from a year earlier, with the FY2022 full-year figure at $24.7 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q4 2020 stood at $324.1 million, up from -$180000.0 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for KURA reached as high as $324.1 million in Q4 2020 and fell as low as -$180000.0 in Q3 2020.
• Historically, Net Equity Issued and Repurchased has averaged $70.5 million across 4 years, with a median of $28.8 million in 2018.
• Across the five-year window, Net Equity Issued and Repurchased tumbled 1150.0% in 2019 and soared 1543433.33% in 2020, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$4000.0 in 2017, then surged by 150.0% to $2000.0 in 2018, then tumbled by 1150.0% to -$21000.0 in 2019, then surged by 1543433.33% to $324.1 million in 2020.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $324.1 million in Q4 2020, -$180000.0 in Q3 2020, and -$21000.0 in Q4 2019.